Estudio naturalista comparativo de la eficacia y tolerancia de los nuevos antidepresivos

Actas Espanolas de Psiquiatria

Volumn 26, Issue 6, 1998, Pages 351-357

  Arias, F ^a   Padin J J ^b   Gilaberte, I ^c   Varillas, P ^a   Sanchez R ^a   Gomez S ^a   Garcia D ^a  

^a Área de Salud de Zamora   (Spain)

^b HOSPITAL VIRGEN DE LA LUZ   (Spain)

^c ELI LILLY AND COMPANY   (Spain)

Author keywords

Efficacy; Naturalistic study; Selective Serotonin Re uptake Inhibitors; Tolerability; Venlafaxine

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 3042900165     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Judd LL. Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharm 1995;10(Suppl. 4):5-10.
2. Sherwood N, Hindmard I. A comparison of five commonly presented antidepressants with particular reference to their behavioural toxicity. Human Psychopharmacol 1993;8:917-22.
3. Anderson MI, Tomenson DM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharm 1994;8:238-49.
4. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharm 1986;90:131-8.
5. Fabre LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psych 1992;53(suppl.):40-3.
6. Kasper S, Lepine JP, Mendlewicz J, et al. Efficacy, safety and indications for tricyclic and the newer antidepressants. Depression 1995;2:127-37.
7. Kocsis JH, Zisook S, Davidson J, et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes. Am J Psych 1997;154:390-5.
8. Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed outpatients. Br J Psychiatry 1988;153(suppl. 3):64-8.
9. Möller HJ, Fuger J, Kasper S. Efficacy of new generation antidepressants: Meta-analysis of imipramine controlled studies. Pharmacopsychiat 1994;27:215-23.
10. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 1989;37:713-38.
11. Schweizer E, Feighner J, Mandos LA, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
12. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. Imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46:53-8.
13. Bhaumik S, Collacott RA, Gandhi D, et al. A naturalistic study in the use of antidepressants in adults with learning disabilities and affective disorders. Human Psychopharm 1995;10:283-8.
14. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharm 1995;10(suppl. 2):5-14.
15. Preskorn SH. Antidepressant drug selection: Criteria and options. J Clin Psychiatry 1994;55(suppl. A):6-22.
16. Clerc GE, Ruimy P, Verdeau J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharm 1994;9:139-43.
17. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharm 1995;10(suppl. 2):15-20.
18. Aguglia E, Casacchia M, Cassano GB, et al. Doubleblind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharm 1993;8:197-202.
19. Ansseau M, Gabriels A, Loyens J, et al. A double-blind comparison of paroxetine and fluvoxamine in major depression. Eur Neuropsychopharm 1993;3:323-4.
20. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-5.
21. Latimer PR, Ravindran AV, Bernatchez JP, et al. Sertraline versus fluoxetine treatment in major depression. Poster presented at X Congress of World Psychiatric Association, Madrid, 1996.
22. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
23. Hylan TR. Antidepressant use in clinical practice. Royal Soc Med. Roundtable Series 1998;43:11-6.
24. Hylan TR, Menades L, Crown WH et al. Patterns of antidepressant use and their relation to clinical outcomes. Submitted to Journal of Affective Disorders.
25. Katzelnick DJ, Kobak KA, Jefferson, JW, et al. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996;31:374-88.
26. Donoghue JM. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: a naturalistic follow up study. J Serotonin Res 1996;4:267-70.
27. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997;6:235-46.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
29. Spielberger CD. State-Trait Anxiety Inventory. Consulting Psychologists Press. Palo Alto, Calif; 1983.
30. Guy W. Assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication, National Institute of Mental Health, Rockville, MD 1970:217-22.
31. Alonso MP, de Abajo FJ, Martinez JJ, et al. Evolución del consumo de antidepresivos en España. Impacto de los inhibidores selectivos de la recaptacion de serotonina. Med Clin (Barc) 1997;108:161-6.
32. Campbell LK, Robison LM, Skaer TL, Sclar DA. Depression. Interventions and their effectiveness. Dis Manage Health Outcomes 1997;2:223-37.
33. Montejo AL, Gilaberte I, Fombellida C, Hylan TR, Sacristán JA. Patron de uso de los nuevos antidepresivos en la practica clínica. Actas Luso-Esp Neurol Psiquiatr 1998;26:75-82.
34. Dierick M, Ravizza L, Realine R, Martí A. A doubleblind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro Psychopharmacol Biol Psychiatry 1996; 20:57-71.
35. Vanelle JM, Attar-Levy D, Poirier MF, et al. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 1997;170:345-50.
36. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995;56:288-96.
37. Montejo AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: Fluoxetine, Paroxetine, Sertraline, and Fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94.